These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36633771)

  • 41. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability.
    Liu WS; Chan SH; Chang HT; Li GC; Tu YT; Tseng HH; Fu TY; Chang HY; Liou HH; Ger LP; Tsai KW
    Breast Cancer Res; 2018 Apr; 20(1):25. PubMed ID: 29661250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.
    Unruh D; Mirkov S; Wray B; Drumm M; Lamano J; Li YD; Haider QF; Javier R; McCortney K; Saratsis A; Scholtens DM; Sarkaria JN; James CD; Horbinski C
    Clin Cancer Res; 2019 Jan; 25(2):747-759. PubMed ID: 30266764
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
    Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
    PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner.
    Wang G; Sai K; Gong F; Yang Q; Chen F; Lin J
    Mol Med Rep; 2014 May; 9(5):1799-805. PubMed ID: 24626950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolic characterization of aggressive breast cancer cells exhibiting invasive phenotype: impact of non-cytotoxic doses of 2-DG on diminishing invasiveness.
    Fujita M; Imadome K; Somasundaram V; Kawanishi M; Karasawa K; Wink DA
    BMC Cancer; 2020 Sep; 20(1):929. PubMed ID: 32993545
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
    Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
    Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Knockdown of both mitochondrial isocitrate dehydrogenase enzymes in pancreatic beta cells inhibits insulin secretion.
    MacDonald MJ; Brown LJ; Longacre MJ; Stoker SW; Kendrick MA; Hasan NM
    Biochim Biophys Acta; 2013 Nov; 1830(11):5104-11. PubMed ID: 23876293
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.
    Fujiwara H; Tateishi K; Kato H; Nakatsuka T; Yamamoto K; Tanaka Y; Ijichi H; Takahara N; Mizuno S; Kogure H; Matsubara S; Nakai Y; Koike K
    Cancer Sci; 2018 Nov; 109(11):3602-3610. PubMed ID: 30156013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells.
    Filipp FV; Scott DA; Ronai ZA; Osterman AL; Smith JW
    Pigment Cell Melanoma Res; 2012 May; 25(3):375-83. PubMed ID: 22360810
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
    Zhang C; Moore LM; Li X; Yung WK; Zhang W
    Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications.
    Lee S; Urman A; Desai P
    Leuk Lymphoma; 2019 Nov; 60(11):2635-2645. PubMed ID: 30958073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5.
    Yan B; Hu Y; Ma T; Wang Y
    Open Biol; 2018 Oct; 8(10):. PubMed ID: 30305430
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
    Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
    Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High levels of TIMP1 are associated with increased extracellular matrix stiffness in isocitrate dehydrogenase 1-wild type gliomas.
    Luo CH; Shi Y; Liu YQ; Liu Q; Mao M; Luo M; Yang KD; Wang WY; Chen C; Niu Q; Yan ZX; Miao JY; Zhang XN; Zeng H; Li L; Bian XW; Ping YF
    Lab Invest; 2022 Dec; 102(12):1304-1313. PubMed ID: 35882906
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IDH1 mutation promotes proliferation and migration of glioma cells via EMT induction.
    Lu J; Li D; Zeng Y; Wang H; Feng W; Qi S; Yu L
    J BUON; 2019; 24(6):2458-2464. PubMed ID: 31983120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth.
    Nie H; Ju H; Fan J; Shi X; Cheng Y; Cang X; Zheng Z; Duan X; Yi W
    Nat Commun; 2020 Jan; 11(1):36. PubMed ID: 31911580
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
    Calvert AE; Chalastanis A; Wu Y; Hurley LA; Kouri FM; Bi Y; Kachman M; May JL; Bartom E; Hua Y; Mishra RK; Schiltz GE; Dubrovskyi O; Mazar AP; Peter ME; Zheng H; James CD; Burant CF; Chandel NS; Davuluri RV; Horbinski C; Stegh AH
    Cell Rep; 2017 May; 19(9):1858-1873. PubMed ID: 28564604
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1‑mutant tumor cells.
    Zhang Y; Lv W; Li Q; Wang Q; Ru Y; Xiong X; Yan F; Pan T; Lin W; Li X
    Mol Med Rep; 2019 Aug; 20(2):1893-1900. PubMed ID: 31257503
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.
    Duncan CG; Barwick BG; Jin G; Rago C; Kapoor-Vazirani P; Powell DR; Chi JT; Bigner DD; Vertino PM; Yan H
    Genome Res; 2012 Dec; 22(12):2339-55. PubMed ID: 22899282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.